Compensation award — excluded from discretionary-purchase analysis.
Loading…
Traded Jan 2, 2026 · Filed Jan 2, 2026
Cytokinetics's Chief Commercial Officer sold $57K of Cytokinetics shares. It happened by itself, for taxes or pay.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$56,688
Shares × reported transaction price
58 days after results of Nov 5, 2025, 53 days before results of Feb 24, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Filing box checked: sold under a Rule 10b5-1 plan
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +5.5% | +1.1% | +4.4% |
| 30 days | +3.7% | −0.2% | +3.9% |
| 90 days | +6.0% | −4.2% | +10.2% |
| 180 days | +39.7% | +9.2% | +30.4% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.